Why CDK4/6 Inhibitors Are Redefining Breast Cancer Treatment
CDK4/6 inhibitors are redefining cancer treatment by offering targeted therapeutic options that disrupt the cell cycle in cancer cells, particularly in HR+/HER2- breast cancer. These drugs, such as palbociclib, ribociclib, and abemaciclib, are designed to inhibit cyclin-dependent kinases 4 and 6 (CDK4/6), crucial enzymes involved in cell proliferation. Since their approval, CDK4/6 inhibitors have emerged as a standard treatment in combination with endocrine therapy, significantly improving progression-free survival in patients with advanced-stage HR+/HER2- breast cancer. CDK4/6 Inhibitors: Target Patient Pool Analysis The potential target population for CDK4/6 inhibitors extends beyond HR+/HER2- breast cancer. Research presented at ASCO 2024 highlights their promising application in treating other cancers, such as prostate cancer and even triple-negative breast cancer (TNBC), which traditionally lacks targeted therapies. The growing incidence of breast cancer worldwide and the unmet ...